Immuno-Oncology | Specialty

XL092 Plus Atezolizumab Vs Regorafenib Under Investigation in MSS/MSI-Low mCRC

February 7th 2023

The safety and efficacy of a combination regimen comprised of XL092 and atezolizumab is being compared with that of regorafenib monotherapy in patients with microsatellite stable or microsatellite instability–low metastatic colorectal cancer who have progressed on or are intolerant to standard-of-care therapy.

Cemiplimab Plus Chemotherapy Expands First-Line Options in Advanced NSCLC

January 30th 2023

Ana Baramidze, MD, provides background on the FDA approvals of cemiplimab in NSCLC, expands on key efficacy and safety data with cemiplimab from EMPOWER-Lung 3, and discusses the current treatment landscape for patients with advanced NSCLC.

Neoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors

January 30th 2023

Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid tumors.

Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

January 25th 2023

Bavituximab in combination with pembrolizumab produced responses in patients with previously untreated advanced hepatocellular carcinoma.

Neoadjuvant Immunotherapy Elicits Strong Responses in Localized dMMR/MSI-H Colorectal Cancer

January 16th 2023

Neoadjuvant treatment with anti–PD-1 inhibitors induced high rates of complete response and reduced recurrence rates, according to a retrospective analysis of patients with localized mismatch repair-deficient or microsatellite instability–high colorectal cancer.

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14th 2023

A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12th 2023

A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.

CDX-1140 Plus Pembrolizumab Elicits Responses in PD-1/PD-L1–Resistant Solid Tumors

January 12th 2023

The utilization of the anti-CD40 agonist, CDX-1140, in combination with pembrolizumab was generally well tolerated and demonstrated preliminary efficacy in patients with anti–PD-1/PD-L1 resistant, locally advanced or metastatic solid tumors.

Adjuvant Pembrolizumab Improves QOL vs Ipilimumab or HDI in Resected Melanoma

January 10th 2023

Treatment with adjuvant pembrolizumab resulted in favorable quality-of-life outcomes vs high-dose interferon α 2b or ipilimumab in patients with resected melanoma at high risk for relapse.

Neoadjuvant SHR-1701 Increases Response, Resectability in Stage III Unresectable NSCLC

January 8th 2023

Neoadjuvant treatment with SHR-1701 with or without chemotherapy followed by surgery or radiotherapy induced responses in more than half of patients with stage III unresectable non–small cell lung cancer and increased resectability in those assigned to definitive surgery.

INT230-6 Alone, With Ipilimumab Induces Positive OS Results in Metastatic Sarcomas

December 30th 2022

INT230-6 demonstrated direct tumor killing in soft tissue sarcoma and elicits an anti-cancer immune response within the injected tumor both alone and in combination with ipilimumab.

INV-1120 Proves Tolerable in Advanced Solid Tumors, Moves to Expansion in Combination With Pembrolizumab

December 28th 2022

Treatment with INV-1120 was well tolerated and demonstrated preliminary signals of stable disease as a single agent in patients with advanced solid tumors.

Chemoimmunotherapy Regimens Improve Long-term Outcomes in Small Cell Lung Cancer

December 18th 2022

Stephen V. Liu, MD, discusses the effect of the FDA approval of atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in small cell lung cancer.

PD-L1 Status Could Help Inform Patient Selection for IO-Based Therapy in HNSCC

December 15th 2022

Ranee Mehra, MD, discusses the significance of 5-year follow-up data and the subgroup analysis from KEYNOTE-048, the benefits and limitations of IO therapy in head and neck squamous cell carcinoma, and research aiming to expand the role of IO combination regimens in this space.

Frontline Adagrasib Plus Pembrolizumab Elicits Encouraging Clinical Activity in KRAS G12C+ Advanced NSCLC

December 8th 2022

Concurrent adagrasib and pembrolizumab produced preliminary activity when administered as first-line treatment in patients with non–small cell lung cancer harboring a KRAS G12C mutation, irrespective of PD-L1 status, according to data from the KRYSTAL-1 phase 1b and the KRYSTAL-7 phase 2 cohorts.

FDA Approvals of Immunotherapy in Gynecology Oncology

December 7th 2022

In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.

CG0070/Pembrolizumab Combo Shows Promising Efficacy and Tolerability in NMIBC

November 30th 2022

The oncolytic vaccine CG0070 plus pembrolizumab demonstrated encouraging response rates and a tolerable safety profile in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer

November 30th 2022

Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer.

Immunotherapy and You: Checkpoint Inhibitors in Gynecologic Cancers

November 30th 2022

In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.

NT-I7/Pembrolizumab Combo Shows Clinical Efficacy in MSS CRC and Pancreatic Cancer Without Liver Metastasis

November 30th 2022

The combination of NT-I7 and pembrolizumab showed significant clinical activity in checkpoint inhibitor–naïve, relapsed/refractory microsatellite stable colorectal cancer and pancreatic cancer without liver metastasis.